Early antiretroviral therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy : evidence from the Children with HIV Early antiretroviral therapy (CHER) Study.

Simple item page
dc.contributor.authorHainline, Clotilde
dc.contributor.authorTaliep, Reghana
dc.contributor.authorSorour, Gill
dc.contributor.authorNachman, Sharon
dc.contributor.authorRabie, Helena
dc.contributor.authorDobbels, Els
dc.contributor.authorJanse van Rensburg, Anita
dc.contributor.authorCornell, Morna
dc.contributor.authorViolari, Avy
dc.contributor.authorMadhi, Shabir A.
dc.contributor.authorCotton, Mark F.
dc.date.accessioned2011-12-14T13:44:45Z
dc.date.available2011-12-14T13:44:45Z
dc.date.issued2011-10
dc.date.updated2011-11-19T06:18:47Z
dc.descriptionThe original publication is available at http://www.biomedcentral.com/1756-0500/4/448
dc.descriptionPublication of this article was funded by the Stellenbosch University Open Access Fund.
dc.description.abstractAbstract Background Although otorrhea occurs commonly in HIV-infected infants, there are few data. We compared the incidence of otorrhea in infants receiving early vs deferred ART in the Children with HIV Early Antiretroviral (CHER) trial. Infants aged 6 to 12 weeks of age with confirmed HIV infection and a CD4 percentage greater than or equal to 25% were randomized to early or deferred ART at two sites in South Africa. Medical records from one study site were reviewed for otorrhea. Findings Data were reviewed from the start of the trial in July 2005 until 20 June 2007, when the Data Safety Monitoring Board recommended that randomization to the deferred arm should stop and that all infants in this arm be reviewed for commencing antiretroviral therapy. Infants entered the study at a median of 7.4 weeks of age. Eleven of 38 (29%) on deferred therapy and 7 of 75 (9%) in the early-therapy group developed otorrhea (risk ratio 3.1, 95% confidence interval (CI) 1.31-7.36; p = 0.01). Conclusions Early initiation of antiretroviral therapy is associated with significantly less otorrhea than when a deferred strategy is followed. Trial registration NCT00102960. ClinicalTrials.Goven_ZA
dc.description.versionPeer Revieweden_ZA
dc.format.extent4 p.
dc.identifier.citationHainline, C. et al 2011. Early antiretroviral therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy : evidence from the Children with HIV Early Antiretroviral therapy (CHER) study. BMC Research Notes. 4(1):448-151.en_ZA
dc.identifier.issnhttp://dx.doi.org/10.1186/1756-0500-4-448
dc.identifier.urihttp://hdl.handle.net/10019.1/18172
dc.language.isoen_ZAen_ZA
dc.language.rfc3066en
dc.rights.holderHainline et al.; licensee BioMed Central Ltd.en_ZA
dc.subjectHIV-positive children -- Antiretroviral treatment -- Otitis mediaen_ZA
dc.subjectHIV-positive children and deafness -- Developing countries -- Researchen_ZA
dc.subjectHearing impaired children -- Diagnosis -- Developing countriesen_ZA
dc.titleEarly antiretroviral therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy : evidence from the Children with HIV Early antiretroviral therapy (CHER) Study.en_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
1756-0500-4-448.xml
Size:
31.03 KB
Format:
Extensible Markup Language
Description:
Download
Thumbnail Image
Name:
1756-0500-4-448.pdf
Size:
212.32 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Paediatrics and Child Health)